Non-Small Cell Lung Cancer Therapeutics Market to Touch US$15.1 Bn by 2023
The global non-small cell lung cancer therapeutics market is characterized by many players operating in the industry, but Genentech, a Roche company has been identified as the leader in 2014 accounting for 36% of the revenue share, by Transparency Market Research (TMR). Some of the other players in the market include: Bristol-Myers Squibb, AstraZeneca plc, Celgene Corporation, Boehringer Ingelheim, Novartis AG, Pfizer, Inc., and Eli Lilly and Company. There exists a moderate competition among existing players, which comprise both branded...
View full press release